Literature DB >> 2488364

Treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) with intraperitoneal cefazolin and gentamicin.

J Weber1, E Staerz, T Mettang, C Machleidt, U Kuhlmann.   

Abstract

Between 1983 and 1988 57 peritonitis episodes in an unselected patient population were initially treated with intraperitoneal cefazolin and gentamicin. The loading dose consisted of 500 mg cefazolin/L dialysate and 40 mg gentamicin/L dialysate. The maintenance dosage was 125 mg cefazolin and 8 mg gentamicin per liter dialysate. Forty-five (78.9%) patients were primarily cured with this regimen (responder group = RG). Twelve patients (21.1%) did not respond to the initial therapy (nonresponder group = NG). Eight peritonitis episodes in the NG (14.0% of all patients) were caused by tunnel infections and 2 by diverticulitis (3.5%). The cure rate in patients without tunnel infection or bowel disease was 95.7%. A relapse occurred in 2 patients (3.5%). Duration of therapy was assessed by daily white blood cell count (WBC) in the effluent and treatment was discontinued when the WBC was less than 100/microliters for 3 days. The mean duration of therapy with cefazolin and gentamicin was 8.1 days in the RG and 6.0 days in the NG. Nonresponders were subsequently treated with a modified antibiotic regimen on an average 11.9 days.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2488364

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  4 in total

1.  Influence of intraperitoneal gentamicin on peritoneal transport in IPD patients.

Authors:  L Janicka; M Majdan; J Solski; E Baranowska-Daca; E Kimak
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

2.  Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study).

Authors:  Julie M Varghese; Jason A Roberts; Steven C Wallis; Robert J Boots; Helen Healy; Robert G Fassett; Jeffrey Lipman; Dwarakanathan Ranganathan
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-14       Impact factor: 8.237

3.  Microbiological Surveillance of Peritoneal Dialysis Associated Peritonitis: Antimicrobial Susceptibility Profiles of a Referral Center in GERMANY over 32 Years.

Authors:  Daniel Kitterer; Joerg Latus; Christoph Pöhlmann; M Dominik Alscher; Martin Kimmel
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

4.  Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study.

Authors:  Dwarakanathan Ranganathan; Julie M Varghese; Robert G Fassett; Jeffrey Lipman; Vincent D'Intini; Helen Healy; Jason A Roberts
Journal:  BMC Nephrol       Date:  2009-12-16       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.